University of Copenhagen has divulged 4-hydroxypyridine and 4-hydroxyquinoline derivatives acting as G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of fibrosis, diabetes, inflammatory and cognitive disorders.

Lead Discovery Center GmbH has described 3-substituted 1H-pyrrolo[2,3-b]-pyridines acting as G protein-coupled receptor kinase 5 (GRK5) inhibitors reported to be useful for the treatment of cancer, inflammatory, immunological, metabolic and cardiovascular disorders.

Sanofi SA has divulged substituted pyrrolo[2,3-d]pyrimidines acting as leucine-rich repeat kinase 2 (LRRK2; dardarin and/or G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Lewy body dementia, progressive supranuclear palsy, frontotemporal dementia and Niemann-Pick disease.

Blueprint Medicines Corp. has identified substituted pyrimidinyl-pyrazoles acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2, reported to be useful for the treatment of cancer.

Scripps Research has synthesized 3C-Like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19).

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed isocitrate dehydrogenase (NADP+) (IDPc, IDH1) mutant inhibitors reported to be useful for the treatment of cancer.

Erasca Inc. has described tricyclic GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Beijing Innocare Pharma Tech Co. Ltd. has divulged heterocyclic compounds acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for treatment of cancer.

Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have identified benzoxazinone derivatives acting as mineralocorticoid receptor (MR) antagonists reported to be useful for the treatment of diabetic nephropathy.

Glaxosmithkline Intellectual Property Ltd. has synthesized cytochrome bc1 complex (complex III) (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria.